Desjardins M, Iachimov D, Mousseau S, Doyon-Plourde P, Brousseau N, Rallu F, Quach C
Medical Microbiology and Infectious Diseases, Centre Hospitalier de l'Université de Montréal, Montréal, QC.
Department of Microbiology, Infectious Diseases, and Immunology, Faculty of Medicine, University of Montreal, Montréal, QC.
Can Commun Dis Rep. 2018 Sep 6;44(9):190-195. doi: 10.14745/ccdr.v44i09a01.
The introduction of the acellular pertussis vaccine may have changed the epidemiological and clinical features of pertussis in Canadian children.
To describe the demographics, clinical presentation and outcomes of children and adolescents with pertussis presenting to a tertiary care hospital.
Retrospective cohort of consecutive patients evaluated at the Centre Hospitalier Universitaire Sainte-Justine (CHUSJ) and tested with a bacterial multiplex real-time polymerase chain reaction (PCR) for or between June 2015 and March 2017. Demographics, clinical presentations and outcomes were described for positive test results. The Modified Preziosi Scale was used to assess disease severity; severe disease was defined as a score ≥7.
The age distribution of the 144 positive patients with a clinical encounter at CHUSJ was as follows: less than three months (n=25/144, 17.4%), four months to nine years (n=63/144, 43.8%) and 10 to 18 years (n=56/144, 38.9%). The most common symptoms at presentation were paroxysmal cough (70.1%), post-tussive emesis (47.2%) and coryza (33.3%). Over 84.0% of cases in infants less than three months of age had severe pertussis (92.0% required hospitalization and 28.0% intensive care admission). In children four months to nine years of age, 22.2% had severe pertussis and 11.1% required hospitalization. Only two (3.6%) children greater than 10 years had severe disease.
Pertussis still affects children of all ages in Quebec. In older children, it tends to be a milder disease. When it affects infants, who do not yet have full protection from pertussis vaccination, it often causes severe disease, especially in those less than three months of age. This evidence further supports the implementation of a pertussis vaccination program in pregnant women.
无细胞百日咳疫苗的引入可能改变了加拿大儿童百日咳的流行病学和临床特征。
描述在一家三级护理医院就诊的百日咳儿童和青少年的人口统计学特征、临床表现及转归。
对2015年6月至2017年3月在圣贾斯汀大学中心医院(CHUSJ)接受评估并采用细菌多重实时聚合酶链反应(PCR)检测百日咳杆菌或博德特氏菌的连续患者进行回顾性队列研究。对检测结果呈阳性的患者描述其人口统计学特征、临床表现及转归。采用改良普雷齐奥西量表评估疾病严重程度;严重疾病定义为评分≥7分。
在CHUSJ有临床就诊经历的144例检测结果呈阳性的患者年龄分布如下:小于3个月(n = 25/144,17.4%),4个月至9岁(n = 63/144,43.8%),10至18岁(n = 56/144,38.9%)。就诊时最常见的症状为阵发性咳嗽(70.1%)、咳嗽后呕吐(47.2%)和流涕(33.3%)。小于3个月的婴儿中超过84.0%患有严重百日咳(92.0%需要住院治疗,28.0%需要入住重症监护病房)。在4个月至9岁的儿童中,22.2%患有严重百日咳,11.1%需要住院治疗。10岁以上儿童中仅有2例(3.6%)患有严重疾病。
百日咳仍影响魁北克所有年龄段的儿童。在年龄较大的儿童中,病情往往较轻。当百日咳影响尚未获得百日咳疫苗充分保护的婴儿时,通常会导致严重疾病,尤其是在小于3个月的婴儿中。这一证据进一步支持在孕妇中实施百日咳疫苗接种计划。